Search In this Thesis
   Search In this Thesis  
العنوان
Evaluation of the Efficacy and Safety of Polydioxanone threads in androgenetic alopecia in females /
المؤلف
El-Shahawy, Heba Mohamed Abd El-Hay.
هيئة الاعداد
باحث / Heba Mohamed Abd El- Hay Elshahawy
مشرف / Zainab Abd Elsamad Ibrahim
مشرف / Yasmina Ahmed El Attar
مشرف / Doaa Salah Hegab
الموضوع
Dermatology.
تاريخ النشر
2021.
عدد الصفحات
p. 113 :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الأمراض الجلدية
تاريخ الإجازة
22/8/2021
مكان الإجازة
جامعة طنطا - كلية الطب - الامراض الجلدية والتناسلية
الفهرس
Only 14 pages are availabe for public view

from 145

from 145

Abstract

Female pattern hair loss (FPHL) is the most common cause of alopecia in women, characterized by diffuse nonscarring hair loss in frontal, central, and parietal areas of the scalp. Pathophysiology of FPHL is still not well known, and it is probably a multifactorial genetic trait.
Polydioxanone (PDO) filament is a synthetic absorbable suture, which is prepared from polyester, poly (p-dioxanone). It has high flexibility, high retention strength, non- allergenic nature and a slow absorption rate (6-8 months). The exact mechanism of action of hair growth stimulation by PDO threads remains speculative. However, it is likely that it is similar to that of microneedling, probably involving enhanced expression of hair-related genes and release of growth factors like platelet-derived growth factor (PDGF), and possibly, direct activation of stem cells in the hair bulge area. This study was conducted at Tanta University hospitals aiming to evaluate efficacy and safety of PDO threads in treatment of female patients with AGA alone or combined with PRP in the treatment of the disease. This study included 30 female patients with AGA. Patients were subdivided randomly into 3 equal groups; A, B and C with 10 patients at each group. Patients of group A were treated with PDO threads only (single session). Patients of group B were treated with PDO threads and additional PRP (2 sessions: 2 &6 weeks after threads insertion). Patients of group C were treated with PRP only (2 sessions: 4 weeks apart) as a control group.